Acebilustat

Leukotriene A4 hydrolase inhibitor reducing inflammation

Phase of research

Phase Two Clinical Trial

How it helps

Anti-Inflammatory

General information

Acebilustat is a small-molecule drug under investigation. It is used in studies and not yet available as a human pharmaceutical. It is a leukotriene A4 hydrolase inhibitor with an effect on inflammation biomarkers. In relation to cystic fibrosis, our AIM tool found the data that acebilustat reduces both sputum and blood biomarkers related to inflammation in patients with cystic fibrosis.

Acebilustat on PubChem
Acebilustat on DrugBank

Synonyms

CTX-4430

Marketed as

N/A

Dietary sources

N/A

Structure not available

C29H27N3O4

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
General effect
1 1.95
Link Tested on Impact factor Notes
Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis. humans 1.95

Does not treat

Mutation Number of sources Average impact factor